- Trial phase
- Approved (Armenia only); Phase 3 (US/EU)
- Time to market
- Approved in Armenia (conditional, one-year authorization). No FDA or EMA approval timeline has been announced; the Phase 3 ROBBIN trial is expected to begin dosing in Q1 2027, meaning a potential US/EU approval, if successful, is likely several years away.
- Why 4/10
- No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled within the next ~12 months. The Armenia approval is a small-market milestone, not a share-price binary. The next major catalyst is the Phase 3 ROBBIN trial start (Q1 2027), which is not a binary readout. Evamplix is a major value driver for Agenus, but without a near-term binary event the impact score is capped at 4.
The next major catalyst is the start of the Phase 3 ROBBIN trial (first patient dosing expected Q1 2027), not a near-term binary event. The Armenia approval is a commercial milestone but not material for a US-listed stock. Watch for any FDA/EMA regulatory submission announcements or partnership deals, which could be share-price catalysts. The stock has already rallied ~195% YTD, reflecting optimism around BOT+BAL data.
Price Chart
Executive Summary
Evamplix (balstilimab, BAL) is Agenus Inc.'s anti-PD-1 antibody, approved in Armenia in October 2026 as the brand Evamplix for use in combination with Botvymo (botensilimab, BOT) for previously treated MSS metastatic colorectal cancer. This is the drug's first marketing authorization anywhere, but it is conditional and valid for only one year in a small market. The drug remains investigational in the US and EU. Agenus is prioritizing the Phase 3 ROBBIN trial of BOT+BAL in neoadjuvant high-risk stage II/III MSS colon cancer, with first patient dosing expected in Q1 2027 and a readout likely years away. Strong Phase 1b/2 data have been presented at SITC 2026 and ESMO 2026, showing durable survival benefit. The stock trades around $7.05 with a mean analyst price target of $26.33 (268% implied upside) and 8 Buy/Strong Buy ratings versus 1 Hold.
How It Works
Evamplix (balstilimab) is a monoclonal antibody that blocks the PD-1 checkpoint protein on immune T cells. PD-1 acts as a brake on the immune system; by blocking it, balstilimab releases the brakes and allows the immune system to better recognize and attack cancer cells. It is designed to be used in combination with botensilimab (Botvymo), an anti-CTLA-4 antibody that targets a different immune checkpoint, together aiming to activate a broader anti-tumor immune response.
Trial Status
Evamplix (balstilimab) received its first marketing authorization in Armenia in October 2026, in combination with botensilimab, for previously treated MSS metastatic colorectal cancer. In the US and EU, the drug remains investigational. Agenus is preparing to launch the global randomized Phase 3 ROBBIN trial of BOT+BAL in neoadjuvant high-risk stage II/III MSS colon cancer, with first patient dosing expected in Q1 2027. Multiple Phase 1b and Phase 2 trials have been completed or are ongoing across several tumor types, with data presented at SITC 2026 showing more than half of refractory MSS mCRC patients achieved long-term survival, and at ESMO 2026 showing 72% of dMMR colon cancer patients had no detectable cancer at surgery after six weeks of BOT+BAL.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 ROBBIN trial initiation (first patient dosing expected Q1 2027)
- Potential additional country approvals for BOT+BAL beyond Armenia
- Any FDA or EMA regulatory submission announcements
- Future clinical data readouts from ongoing BOT+BAL studies
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AGENUS INC 8-K AGEN ·Originating report